share_log

Craig-Hallum Initiates Coverage On Xeris Biopharma Holdings With Buy Rating, Announces Price Target of $4.5

Benzinga ·  Aug 28, 2023 09:32

Craig-Hallum analyst Robin Garner initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy rating and announces Price Target of $4.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment